{
    "clinical_study": {
        "@rank": "48783", 
        "acronym": "TARGET-REA", 
        "brief_summary": {
            "textblock": "this study aims to verify the adequacy of doses of antibiotics prescribed in clinical\n      practice for the treatment of ventilated acquired pneumonia (VAP) in the intensive care unit\n      (ICU) with the pharmacodynamic efficacy criteria considered relevant literature. The impact\n      of these pharmacodynamic parameters on the clinical and microbiological VAP will be\n      evaluated."
        }, 
        "brief_title": "Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ventilator-associated Pneumonia", 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia", 
                "Pneumonia, Ventilator-Associated"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Use of mechanical ventilation for more than 48 hours\n\n          2. Clinical suspicion of ventilation-acquired pneumonia (VAP) defined by new\n             radiological persisting infiltrate (or ARDS) AND one of the following features:\n\n             purulent tracheal aspirates OR temperature \u2265 38.3\u00b0C OR leukocytosis> 10 giga/L\n\n          3. High risk of multidrug-resistant bacteria, defined as either at least 6 days of\n             mechanical ventilation OR antibiotic treatment in the previous 15 days\n\n          4. Implementation of a prior distal respiratory sample for microbiological diagnosis by\n             bronchoalveolar lavage (BAL) OR distal sampling by protected catheter (PDP)\n\n          5. Age \u2265 18 years\n\n          6. Implementing a medical examination\n\n          7. Obtain the written consent of the patient, one of its relatives or trusted person\n             previously designated or emergency clause.\n\n        Exclusion Criteria:\n\n          1. Pregnant woman\n\n          2. Expected death within 72 hours of diagnosis of VAP patient\n\n          3. Dialysis\n\n          4. No affiliation to a social security scheme (beneficiary or legal)\n\n          5. Contraindication to one of classes of molecules used antibiotics (\u03b2-lactam /\n             Fluoroquinolones / Aminoglycosides), contained in the Summary of Product\n             Characteristics for authorization on the market."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pneumonia acquired in mechanically ventilated patients (PAVM)"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127528", 
            "org_study_id": "P1101137"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "olivier.pajot@ch-argenteuil.fr", 
                "last_name": "Olivier Pajot, MD", 
                "phone": "+33 1 34 23 24 15"
            }, 
            "facility": {
                "address": {
                    "city": "Argenteuil", 
                    "country": "France", 
                    "state": "Val d'Oise", 
                    "zip": "95100"
                }, 
                "name": "CH Victor Dupouy"
            }, 
            "investigator": {
                "last_name": "Olivier Pajot, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care: Pharmacodynamic Evaluation and Impact.", 
        "overall_contact": {
            "email": "olivier.pajot@ch-argenteuil.fr", 
            "last_name": "Olivier Pajot, MD", 
            "phone": "+33 1 34 23 24 51"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "proportion of patients for whom the pharmacodynamic target defined a priori according to data from the literature is reached for each antibiotic anti Gram-negative bacillus used empirically activity (including \u03b2-lactams, fluoroquinolones and aminoglycosides)", 
            "measure": "adequate antibiotics", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127528"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Bacterial species in question, defined as any bacteria isolated in significant amounts on the diagnostic breath sampling", 
                "measure": "Bacterial species", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "ratio of the peak serum level (Cmax) on the minimal inhibitory concentration (MIC), ie Cmax/MIC ratio (for aminoglycosides and fluoroquinolones): distribution in the population and proportion of patients with Cmax/MIC> 10\nratio of the Area Under the serum concentration time Curve (AUC) on the MIC, ie AUC/MIC ratio (for fluoroquinolones) : distribution in the population and proportion of patients with an AUC/MIC ratio> 125\npercentage of time spent above the MIC between 2 injections, and trough/MIC ratio (for \u03b2-lactams): distribution in the population and proportion of patients with a T>MIC of 100% (intermittent infusion) or trough/MIC> 4 (continuous infusion)", 
                "measure": "Distribution of the main pharmacodynamic parameters", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "defined as a bacterial count from distal respiratory sample realized during the third day of treatment, less than the threshold for each isolated Gram negative bacilli initially beyond these thresholds", 
                "measure": "Eradication of gram negative bacilli responsible for VAP", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Death", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Number of days alive without mechanical ventilation", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "defined as patient alive with Clinical Pulmonary Infection Score (CPIS) <8", 
                "measure": "Clinical recovery", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "repeated measures every 48h for 8 days", 
                "measure": "Score of organ failure (SOFA)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}